Business Wire

GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI

12.5.2026 03:00:00 CEST | Business Wire | Press Release

Share

GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/

GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI

At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure.

  • Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment.
  • Deployable: modular clusters engineered for rapid implementation across diverse environments.
  • Happening: AI systems actively running, delivering outcomes, and sustaining operations in the real world.

“AI-ready” in the Infrastructure Era

AI workloads now span centralized training clusters, distributed inference deployments, and physical environments where machines must act on real-time data. Each stage demands infrastructure that functions as a coordinated system, not a collection of individual components. Deployment speed, operational stability, and long-term efficiency have become the defining measures of AI infrastructure maturity.

GIGABYTE anchors this capability in GAIFA (GIGABYTE AI Factory Accelerator), a purpose-built AI factory in Taiwan that integrates latest compute platforms, high-speed networking, and GIGABYTE's own management software into a fully validated, end-to-end architecture. More than a testing environment, GAIFA represents how an AI factory can be built, validated, and prepared for deployment at scale.

Built for Deployment

Deploying AI infrastructure quickly is becoming a critical differentiator. It requires systems designed to be built, delivered, and operational from day one.

GIGABYTE addresses this with a modular, prefabricated infrastructure approach that integrates compute, cooling, and power into deployable units. These systems are designed to shorten deployment timelines while enabling organizations to scale AI capacity without the delays of traditional data center construction.

GIGABYTE's portfolio supports AI workloads across every stage of operation and is unified through GPM (GIGABYTE POD Manager). This software platform provides visibility and control across AI data center infrastructure, enabling operators to manage resources, optimize workloads, and maintain stability as systems scale.

AI Happening: From Physical Automation to Clinical Decision Support

The most compelling measure of AI infrastructure is what it enables in the real world. GIGABYTE demonstrates this across physical AI automation and healthcare.

In physical AI automation, GIGABYTE presents a real-to-sim-to-real pipeline showing how AI models move from simulation into robotic systems performing precise tasks in real time—a working example of Physical AI in operation, not a research demonstration.

In healthcare, GIGABYTE brings AI inference to the point of care, supporting applications including real-time polyp detection, bone marrow analysis, and pulmonary imaging. All inference runs locally, ensuring data privacy and faster clinical decision-making.

Across both domains, AI is moving closer to where data is generated and decisions are made, delivering faster response, improved accuracy, and more efficient workflows.

GIGABYTE invites all visitors around the world to engage with AI infrastructure that has moved beyond the planning stage. With "Future Landing," GIGABYTE is not only presenting a vision of what AI could become, but also demonstrating what it looks like when ready, deployed, and already operating in the real world. In addition of its 1st floor exhibit, GIGABYTE will also present a dedicated exhibit on the 4th floor, featuring AI solutions for edge and end-user applications, including systems from its AI TOP series, demonstrating how its AI capabilities extend from infrastructure to deskside scenarios.

GIGABYTE@COMPUTEX 2026
https://www.gigabyte.com/Events/Computex
June 2-5, 2026
TaiNEX, Hall 1
Enterprise(1F K0802) Consumer(4F M0520)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260505299592/en/

Contacts

Media Contact: brand@gigabyte.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press Release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press Release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press Release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press Release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press Release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye